FDA authorizes blood purification device to treat COVID-19
The Food and Drug Administration today issued an emergency use authorization for a pair of blood purification systems to treat adult COVID-19 patients admitted to the intensive care unit with severe respiratory illness. The authorized devices filter patients’ blood to remove excess proteins that can cause respiratory or organ failure. The EUA applies to Terumo BCT Inc.’s Spectra Optia Apheresis System and Marker Therapeutics AG’s Depuro D2000 Adsorption Cartridge
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…